Image Place holder

Hien Duong Liu, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Hodgkin Lymphoma , Non-Hodgkin Lymphoma

Dr. Hien Liu is Medical Director of the Apheresis Unit and an Associate Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Liu earned her MD from the University of Michigan Medical School. She completed an Internal Medicine Residency at Michigan State University/Grand Rapids Medical Education and Research Center. Dr. Liu completed a Hematology/Oncology Fellowship at Cleveland Clinic Foundation, where she also served as Chief Fellow. Prior to joining Moffitt, Dr. Liu was an Assistant Professor at Cleveland Clinic Lerner College of Medicine and Associate Member at Case Comprehensive Cancer Center, Cleveland, Ohio. Dr. Liu is an experienced blood and marrow transplant physician, specializing in autologous and allogeneic transplant for lymphoid malignancies, as well as chimeric antigen receptor (CAR) T-cell therapy. Her clinical and research interests include peripheral blood stem cell mobilization strategies, leukapheresis for CAR T, and therapeutic photopheresis. Dr. Liu leads the Moffitt Apheresis Unit, where peripheral blood stem cell collections for hematopoietic stem cell transplant donors and cellular therapy patients are performed. In addition, she is part of the team of lymphoma physicians that see and perform CAR T-cell therapy for lymphoid cancers.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine
  • Hematology
  • Internal Medicine

Fellowship:

  • Cleveland Clinic Foundation - Hematology/Oncology

Residency:

  • Michigan State University/Grand Rapids Medical Education and Research Center - Internal Medicine

Medical School:

  • University of Michigan Medical School - MD
Participating Trials

CLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Condition: Malignant Hematology
Intervention: Rituxan (rituximab); Rituxan Hycela; rituximab
Open

CLINICAL TRIAL 19341
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Condition: Immunotherapy
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; MESNA; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19484
Collection of Blood Mononuclear Cells by Apheresis from Compensated Volunteer Healthy Donors
Condition: Healthy Subjects
Intervention: Not Applicable
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Patel SS, Rybicki LA, Corrigan D, Dumont C, Bolwell B, Dean R, Figueroa P, Hanna R, Liu H, Gerds AT, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Ricci K, Sobecks R, Lu W, Hamilton BK, Majhail NS. Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018 Oct. Pubmedid: 30375493.
  • Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Stanghellini MTL, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers ME, Shaw BE, Petriček I. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Tr. 2018 Nov. Pubmedid: 30481594.
  • Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Majhail NS, Hamilton BK. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2018 May;24(5):1029-1034. Pubmedid: 29369800. Pmcid: PMC5953837.
  • Winter A, Rybicki L, Shah SN, Jagadeesh D, Gerds AT, Hamilton BK, Liu H, Dean R, Sobecks R, Pohlman B, Smith M, Kalaycio M, Bolwell BJ, Majhail NS, Hill BT. Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2018 May;59(5):1195-1201. Pubmedid: 28853617.
  • Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Daratumumab proves safe and highly effective in AL amyloidosis. Brit J Haematol. 2018 Jun. Pubmedid: 29938774.
  • Khouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, Hill B, Dean R, Lazaryan A, Hamilton B, Andresen S, Sobecks R, Bolwell B, Liu H. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. J Clin Apher. 2018 Jun;33(3):303-309. Pubmedid: 29134688.
  • Sawalha Y, Hill BT, Rybicki LA, Sun D, Dean RM, Jagadeesh D, Hamilton BK, Gerds AT, Sobecks RM, Andresen S, Liu HK, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, Smith MR. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e95-e102. Pubmedid: 29208403.
  • Mustafa Ali M, Corrigan DM, Rybicki LA, Yurch MA, Cherni K, Liu H, Dean R, Hamilton B, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks R. Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma. Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):253-256. Pubmedid: 29705567.
  • Bates D, Bolwell B, Majhail NS, Rybicki L, Yurch M, Abounader D, Kohuth J, Jarancik S, Koniarczyk H, McLellan L, Dabney J, Lawrence C, Gallagher L, Kalaycio M, Sobecks R, Dean R, Hill B, Pohlman B, Hamilton BK, Gerds AT, Jagadeesh D, Liu HD. Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study. Biol Blood Marrow Tr. 2017 Sep;23(9):1567-1572. Pubmedid: 28533058.
  • Mustafa Ali M, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks RM. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biol Blood Marrow Tr. 2017 May;23(5):776-781. Pubmedid: 28108271.
  • Gokhale A, Quraishy N, Veemara V, Howdyshell H, Murray L, Royer J, Salmi L, Ricci K, Liu H. Clotting during autologous hematopoietic progenitor cells collection. J Clin Apher. 2017 Dec;32(6):560-561. Pubmedid: 28485035.
  • Gokhale A, Quraishy N, Royer J, Howdyshell H, Murray L, Salmi L, Veemara V, Ricci K, Liu H. Centrifuge bowl leak during extracorporeal photopheresis. Transfusion. 2017 Aug;57(8):1860-1861. Pubmedid: 28782819.
  • Hong S, Rybicki L, Abounader DM, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma. Bone Marrow Transplant. 2016 Sep;51(9):1191-1196. Pubmedid: 27111046.
  • Liu HD. The Cost of Mobilization. Biol Blood Marrow Tr. 2016 Oct;22(10):1735-1736. Pubmedid: 27538375.
  • Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers ME, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JL, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016 11;128(19):2350-2358. Pubmedid: 27625357. Pmcid: PMC5106113.
  • Hill BT, Rybicki L, Carlstrom KD, Jagadeesh D, Gerds A, Hamilton B, Liu H, Dean R, Sobecks R, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Tr. 2016 09;22(9):1588-1595. Pubmedid: 27343718.
  • Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Tr. 2016 06;22(6):1141-1144. Pubmedid: 26995694.
  • Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. Bone Marrow Transplant. 2016 05;51(5):732-734. Pubmedid: 26726941.